-
7m 26sPart 3 | Session 12 FAST III - FFR vs vFFR to Guide Revascularisation
-
5m 34sPart 3 | Session 13 AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
-
4m 5sPart 3 | Session 14 CORALreef — Durability of Enlicitide for Lipid Lowering in Hypercholesterolaemia
-
5m 18sPart 4 | Session 1 STEMI-DTU, GOFRESH, and HI-PEITHO
-
3m 7sPart 4 | Session 2 SURPASS CVOT, HI-PEITHO, SURVIV
-
5m 8sPart 4 | Session 3 Top Takeaways from the 2026 Dyslipidaemia Guidelines
-
2m 21sPart 4 | Session 4 3 ACC.26 Highlights for the Cardiology Pharmacist
-
10m 19s
-
25m 1sPart 1 | Session 1 CHAMPION-AF: LAA Closure vs OAC in AF Outcomes
-
18m 33sPart 1 | Session 2 ALERT: Under-treatment in AS and MR
-
26m 37sPart 1 | Session 3 PRO-TAVI: TAVI With or Without Routine PCI
-
19m 43sPart 1 | Session 4 Dig-RHD: Digoxin in Rheumatic Heart Disease
-
6m 44sPart 2 | Session 1 VESALIUS-CV, KARDINAL, CHIP-BCIS3 & More
-
9m 4sPart 2 | Session 2 CHAMPION-AF, HI-PEITHO, STEMI-DTU
-
5m 51sPart 3 | Session 1 Door to Unload Randomized Clinical Trial
-
5m 58sPart 3 | Session 2 ALL-RISE – Coronary Physiology From Angiography vs Pressure Wire for PCI
-
6m 28s
-
8m 35sPart 3 | Session 4 The STEMI-DTU Trial – Primary Unloading and Delayed Reperfusion in STEMI
-
4m 47s
-
13m 52sPart 3 | Session 6 ACC 2026 with Dr Mehran: Leadership, Vision, and the Future of the College
-
5m 17sPart 3 | Session 7 Heart Failure in 2026: Practical Therapy Lessons From ACC.26
-
6m 14sPart 3 | Session 8 RECOVER-Autonomic - Ivabradine for Post-COVID POTS
-
9m 23sPart 3 | Session 9 ORBITA-CTO - PCI Versus Placebo for Chronic Total Occlusion in Stable Angina
-
7m 21sPart 3 | Session 10 CHIP-BCIS3 – Percutaneous LV Unloading in High-Risk PCI
ACC.26 - At ACC.26 in New Orleans, Dr Devi Nair (Arkansas, US) and Dr Vivek Reddy (New York, US) dissect the late-breaking CHAMPION‑AF trial, a large randomized comparison of first-line left atrial appendage closure with WATCHMAN FLX versus continued NOAC therapy in patients with non-valvular AF who can tolerate anticoagulation. They review the trial design, post‑implant antithrombotic and imaging strategy, and dual primary endpoints at 3 years, focusing on how to balance a modest absolute increase in ischaemic stroke/systemic embolism against a substantial reduction in clinically relevant bleeding.
The discussion highlights key controversies: whether a roughly 0.33% per‑year increase in ischaemic events is acceptable for selected patients, how to handle procedure‑related complications in bleeding endpoints, and the true clinical weight of “clinically relevant non‑major” bleeding. The faculty then place CHAMPION‑AF alongside OPTION, OCEAN, ALONE and CLOSURE‑AF, translating this growing evidence base into practical, case-based guidance on when to consider first-line LAA closure versus lifelong NOACs—especially in post‑ablation and intermediate-risk patients—and what clinicians should look for in forthcoming 5‑year data.
Keep up-to-date with our video collection from the American College of Cardiology's 75th Annual Scientific Session, bringing you the latest from late-breaking science, featured research, and clinical horizon sessions.
Catch our congress preview and wrap-up in the NVM Cardiology Meeting Reflections series, alongside concise Expert Interviews with leading faculty distilling the key take-home messages for clinical practice — plus in-depth Highlights breaking down the most impactful trials of the meeting.
More from this programme
Part 1
Late-Breaker Discussions
Part 2
Between the Sessions with Dr Purvi Parwani
Part 3
Expert Interviews
Part 4
Highlights
Part 5
Market Watch
Part 6
NVM Cardiology Meeting Reflections
Faculty Biographies
Vivek Reddy
Director of Cardiac Arrhythmia Services
Dr. Vivek Y. Reddy is a renowned cardiac electrophysiologist based in New York, currently serving as Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Director of Electrophysiology for the Mount Sinai Health System. He holds the Leona M. and Harry B. Helmsley Charitable Trust Professorship of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine at Mount Sinai. Dr. Reddy is recognized internationally for his groundbreaking clinical work in heart rhythm disorders, including atrial fibrillation, ventricular tachycardia, and the development of device-based stroke prevention strategies. Under his leadership, Mount Sinai has been the lead investigational site for numerous multinational clinical trials, including those exploring pulsed field ablation and other emerging arrhythmia technologies. In 2014, he implanted the world’s first miniature leadless pacemaker in the United States at The Mount Sinai Hospital, marking a major advance in pacing…
Devi Nair
Director of Cardiac Electrophysiology
Dr Devi Nair is a cardiologist and the Director of Cardiac Electrophysiology at St Bernard's Heart and Vascular Center in Arkansas, US. She also holds the position of Assistant Professor of Medicine at the University of Arkansas for Medical Sciences. As an international leader in cardiac rhythm management, Dr Devi Nair specialises in cardiac devices and cardiac ablation therapy.
Dr Devi Nair has won the People's Choice award for the best cardiologist in Jonesboro for the last 5 years.
Dr Devi Nair has made significant contributions to the field through her numerous publications in leading international medical journals. Her extensive medical training began at the University of Kerala, India, followed by residencies at Columbia University College of Physicians & Surgeons and St Luke's Roosevelt Hospital Center in New York, US. She further honed her expertise with fellowships at Case Western Reserve University, US.
Comments